A share price of Editas Medicine Inc [EDIT] is currently trading at $3.17, down -3.35%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The EDIT shares have gain 9.31% over the last week, with a monthly amount glided 1.60%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Editas Medicine Inc [NASDAQ: EDIT] stock has seen the most recent analyst activity on November 06, 2024, when Evercore ISI upgraded its rating to a Outperform. Previously, Raymond James downgraded its rating to Mkt Perform on November 04, 2024. On August 08, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $15 on the stock. Morgan Stanley upgraded its rating to a Equal-Weight but stick to its price target of $7 on May 09, 2024. Citigroup upgraded its rating to a Buy but $11 remained the price target by the analyst firm on October 24, 2023. JP Morgan upgraded its rating to Neutral for this stock on October 18, 2023, but kept the price target unchanged to $8. In a note dated October 17, 2023, Cantor Fitzgerald downgraded an Neutral rating on this stock.
Editas Medicine Inc experienced fluctuations in its stock price throughout the past year between $2.70 and $11.69. Currently, Wall Street analysts expect the stock to reach $13.5 within the next 12 months. Editas Medicine Inc [NASDAQ: EDIT] shares were valued at $3.17 at the most recent close of the market. An investor can expect a potential return of 325.87% based on the average EDIT price forecast.
Analyzing the EDIT fundamentals
Trailing Twelve Months sales for Editas Medicine Inc [NASDAQ:EDIT] were 61.76M which represents -98.86% decline. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -3.64%, Pretax Profit Margin comes in at -3.41%, and Net Profit Margin reading is -3.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.64, Equity is -0.8 and Total Capital is -0.88. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.09 points at the first support level, and at 3.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.28, and for the 2nd resistance point, it is at 3.38.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Editas Medicine Inc [NASDAQ:EDIT] is 3.75. As well, the Quick Ratio is 3.75, while the Cash Ratio is 1.32. Considering the valuation of this stock, the price to sales ratio is 4.24, the price to book ratio is 1.49.
Transactions by insiders
Recent insider trading involved Mei Baisong, EVP, CHIEF MEDICAL OFFICER, that happened on Sep 04 ’24 when 518.0 shares were sold. CEO, O’Neill Gilmore Neil completed a deal on Sep 04 ’24 to sell 1555.0 shares. Meanwhile, Officer O’Neill Gilmore Neil bought 3000.0 shares on Sep 03 ’24.
